HUE050230T2 - Stabil és szolubilis, VEGF-et gátló antitestek - Google Patents

Stabil és szolubilis, VEGF-et gátló antitestek

Info

Publication number: HUE050230T2
Authority: HU; Hungary
Prior art keywords: stable; inhibiting vegf; soluble antibodies; antibodies inhibiting; soluble
Prior art date: 2008-06-25

Application number

HUE17151756A

Other languages

English (en)

Inventor

Leonardo Borras

David Urech

Tea Gunde

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-06-25

Filing date

2009-06-25

Publication date

2020-11-30

2009-06-25 Application filed by Novartis Ag filed Critical Novartis Ag

2020-11-30 Publication of HUE050230T2 publication Critical patent/HUE050230T2/hu

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Reproductive Health (AREA)
Ophthalmology & Optometry (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Hematology (AREA)

HUE17151756A 2008-06-25 2009-06-25 Stabil és szolubilis, VEGF-et gátló antitestek HUE050230T2 (hu)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date
US7569208P	2008-06-25	2008-06-25
US7569708P	2008-06-25	2008-06-25
US13321208P	2008-06-25	2008-06-25
US15504109P	2009-02-24	2009-02-24

Publications (1)

Publication Number	Publication Date
HUE050230T2 true HUE050230T2 (hu)	2020-11-30

Family

ID=41209803

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
HUE09768693A HUE032894T2 (hu)	2008-06-25	2009-06-25	VEGF-gátló, stabilis és oldható antitestek
HUE17151756A HUE050230T2 (hu)	2008-06-25	2009-06-25	Stabil és szolubilis, VEGF-et gátló antitestek
HUS2000028C HUS2000028I1 (hu)	2008-06-25	2020-07-27	VEGF-gátló, stabilis és oldható antitestek

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
HUE09768693A HUE032894T2 (hu)	2008-06-25	2009-06-25	VEGF-gátló, stabilis és oldható antitestek

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
HUS2000028C HUS2000028I1 (hu)	2008-06-25	2020-07-27	VEGF-gátló, stabilis és oldható antitestek

Country Status (26)

Country	Link
US (5)	US8349322B2 (hu)
EP (3)	EP3216803B1 (hu)
JP (7)	JP5956752B2 (hu)
KR (8)	KR101737466B1 (hu)
CN (3)	CN110372792A (hu)
AU (1)	AU2009264565C1 (hu)
BR (1)	BRPI0914251B1 (hu)
CA (2)	CA3020290A1 (hu)
CL (1)	CL2010001544A1 (hu)
CY (3)	CY1118829T1 (hu)
DK (2)	DK2307454T3 (hu)
ES (2)	ES2622470T3 (hu)
HK (1)	HK1150844A1 (hu)
HR (2)	HRP20170615T1 (hu)
HU (3)	HUE032894T2 (hu)
LT (3)	LT3216803T (hu)
MX (2)	MX2011000011A (hu)
NL (1)	NL301058I2 (hu)
NO (1)	NO2020021I1 (hu)
PH (1)	PH12015501593A1 (hu)
PL (2)	PL3216803T3 (hu)
PT (2)	PT2307454T (hu)
RU (6)	RU2588467C3 (hu)
SI (2)	SI2307454T1 (hu)
WO (1)	WO2009155724A2 (hu)
ZA (1)	ZA201008594B (hu)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2371865B1 (en)	2006-04-07	2017-07-12	Aerpio Therapeutics, Inc.	Antibodies that bind human protein tyrosine phosphatase beta (HPTP-ß) and uses thereof
SI2307457T2 (sl)	2008-06-25	2022-10-28	Novartis Ag	Stabilna in topna protitelesa, ki inhibirajo TNF
EP2752428B8 (en)	2008-06-25	2020-02-26	Novartis Ag	Humanization of rabbit antibodies using a universal antibody framework
KR101737466B1 (ko)	2008-06-25	2017-05-18	에스바테크 - 어 노바티스 컴파니 엘엘씨	Ｖｅｇｆ를 억제하는 안정하고 가용성인 항체
WO2010006454A2 (en) *	2008-06-30	2010-01-21	Esbatech, An Alcon Biomedical Research Unit Llc	Functionalized polypeptides
US8268314B2 (en)	2008-10-08	2012-09-18	Hoffmann-La Roche Inc.	Bispecific anti-VEGF/anti-ANG-2 antibodies
WO2010096941A1 (en)	2009-02-24	2010-09-02	Esbatech, An Alcon Biomedical Research Unit Llc	Methods for identifying immunobinders of cell-surface antigens
KR101741859B1 (ko)	2009-06-22	2017-06-15	암젠 인크	화학적으로 조절된 산화환원 상태를 사용한 단백질의 재폴딩
EP2445924B2 (en)	2009-06-25	2023-12-13	Amgen Inc.	Capture purification processes for proteins expressed in a non-mammalian system
NZ609607A (en) *	2010-10-19	2014-12-24	Mayo Foundation	Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease
UY33679A (es)	2010-10-22	2012-03-30	Esbatech	Anticuerpos estables y solubles
US9527925B2 (en)	2011-04-01	2016-12-27	Boehringer Ingelheim International Gmbh	Bispecific binding molecules binding to VEGF and ANG2
DK2758432T3 (da) *	2011-09-16	2019-06-03	Ucb Biopharma Sprl	Neutraliserende antistoffer mod hovedtoksinerne TcdA og TcdB fra Clostridium difficile
JP2014530244A (ja)	2011-10-13	2014-11-17	エアピオセラピューティックス，インコーポレイテッド	血管漏出症候群および癌を治療する方法
ES2604837T3 (es)	2012-02-02	2017-03-09	Esbatech - A Novartis Company Llc	Formulación de liberación sostenida que contiene anticuerpos para administración ocular
LT2872534T (lt)	2012-07-13	2018-10-25	Roche Glycart Ag	Dvigubai specifiniai anti-vegf/anti-ang-2 antikūnai ir jų panaudojimas akių kraujagyslių ligoms gydyti
CN104995303A (zh)	2012-12-18	2015-10-21	诺华股份有限公司	利用结合乙酰透明质酸的肽标签的组合物和方法
RS60026B1 (sr)	2013-02-18	2020-04-30	Vegenics Pty Ltd	Molekuli koji vezuju ligande i njihove upotrebe
KR101541478B1 (ko)	2013-05-31	2015-08-05	동아쏘시오홀딩스 주식회사	항-vegf 항체 및 이를 포함하는 암 또는 신생혈관형성관련 질환의 예방, 진단 또는 치료용 약학 조성물
EP3013864A1 (en) *	2013-06-26	2016-05-04	Numab AG	Novel antibody frameworks
AU2014286996A1 (en)	2013-07-12	2016-01-07	Iveric Bio, Inc.	Methods for treating or preventing ophthalmological conditions
WO2015076425A1 (ja) *	2013-11-25	2015-05-28	リンク・ジェノミクス株式会社	新規モノクローナル抗体
WO2015173260A1 (en)	2014-05-12	2015-11-19	Formycon Ag	Pre-filled plastic syringe containing a vegf antagonist
EP3160990A2 (en)	2014-06-25	2017-05-03	Novartis AG	Compositions and methods for long acting proteins
EP3160991A2 (en)	2014-06-25	2017-05-03	Novartis AG	Compositions and methods for long acting proteins
US9840553B2 (en)	2014-06-28	2017-12-12	Kodiak Sciences Inc.	Dual PDGF/VEGF antagonists
GB201412658D0 (en)	2014-07-16	2014-08-27	Ucb Biopharma Sprl	Molecules
KR102390359B1 (ko)	2014-09-29	2022-04-22	삼성전자주식회사	폴리펩타이드, 이를 포함하는 항 VEGF 항체 및 항 c-Met/항 VEGF 이중 특이 항체
TWI761959B (zh) *	2014-11-07	2022-04-21	瑞士商諾華公司	治療眼部疾病之方法
KR20170080604A (ko)	2014-11-10	2017-07-10	제넨테크, 인크.	항-인터류킨-33 항체 및 그것의 용도
MX2017009759A (es) *	2015-01-28	2017-10-27	Pfizer	Formulacion de anticuerpo del anti-factor de crecimiento endotelial vascular (vegf) acuosa estable.
JP6924148B2 (ja)	2015-04-16	2021-08-25	ハー・ルンドベック・アクチエゼルスカベット	抗ｐａｃａｐ抗体及びそれらの使用
US10851399B2 (en) *	2015-06-25	2020-12-01	Native Microbials, Inc.	Methods, apparatuses, and systems for microorganism strain analysis of complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon
GB201601077D0 (en)	2016-01-20	2016-03-02	Ucb Biopharma Sprl	Antibody molecule
GB201601073D0 (en) *	2016-01-20	2016-03-02	Ucb Biopharma Sprl	Antibodies
US20180230540A1 (en)	2015-08-12	2018-08-16	Novartis Ag	Methods of treating ophthalmic disorders
SG10202001808VA (en)	2015-10-30	2020-04-29	Genentech Inc	Anti-htra1 antibodies and methods of use thereof
EP3375875A4 (en) *	2015-11-09	2018-12-05	National University Corporation Kyoto Institute of Technology	SEPARATING AGENT FOR HUMAN SERUM-DERIVED IgG POLYCLONAL ANTIBODIES, AND METHOD FOR SEPARATING HUMAN SERUM-DERIVED IgG POLYCLONAL ANTIBODIES USING SAME
US10925927B2 (en)	2015-11-18	2021-02-23	Formycon Ag	Pre-filled pharmaceutical package comprising a liquid formulation of a VEGF-antagonist
RU2751510C2 (ru)	2015-11-18	2021-07-14	Сио2 Медикал Продактс, Инк.	Фармацевтическая упаковка для офтальмологических составов
US20180326126A1 (en)	2015-11-18	2018-11-15	Formycon Ag	Pre-filled plastic syringe containing a vegf antagonist
GB201521382D0 (en)	2015-12-03	2016-01-20	Ucb Biopharma Sprl	Antibodies
GB201521389D0 (en)	2015-12-03	2016-01-20	Ucb Biopharma Sprl	Method
RU2744860C2 (ru)	2015-12-30	2021-03-16	Кодиак Сайенсиз Инк.	Антитела и их конъюгаты
WO2017119434A1 (ja)	2016-01-06	2017-07-13	株式会社オーダーメードメディカルリサーチ	Ｖｅｇｆとｎｒｐ１との結合を阻害する抗体
US11007259B2 (en)	2016-01-06	2021-05-18	Order-Made Medical Research Inc.	High-affinity anti-VEGF antibody
USD789171S1 (en)	2016-01-21	2017-06-13	Nomis Llc	Right angle drive
WO2017129685A1 (en)	2016-01-26	2017-08-03	Formycon Ag	Liquid formulation of a vegf antagonist
KR20180105704A (ko) *	2016-02-05	2018-09-28	보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템	Egfl6 특이적 단일클론 항체들 및 이의 사용 방법
WO2017156423A2 (en) *	2016-03-11	2017-09-14	Integrated Biotherapeutics, Inc.	Broadly protective antibody cocktails for treatment of filovirus hemorrhagic fever
EP3222673A1 (de) *	2016-03-23	2017-09-27	LANXESS Deutschland GmbH	Metallazopigmente
WO2017181039A1 (en)	2016-04-15	2017-10-19	Alder Biopharmaceuticals, Inc.	Humanized anti-pacap antibodies and uses thereof
MD3479819T2 (ro)	2016-06-30	2024-07-31	Celltrion Inc	Preparat farmaceutic lichid stabil
CN109890982B (zh)	2016-07-08	2023-07-07	基因泰克公司	通过nrf2及其下游目标基因的表达状态和突变状态诊断和治疗癌症的方法
EP3592384A1 (en) *	2017-03-09	2020-01-15	MAB Discovery GmbH	Antibodies specifically binding to human il-1r7
JOP20190245A1 (ar)	2017-04-20	2019-10-15	Novartis Ag	أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
JP7282689B2 (ja)	2017-05-19	2023-05-29	カウンスィルオブサイエンティフィックアンドインダストリアルリサーチ	リフォールディングした組み換えヒト化ラニビズマブの製造方法
WO2018217995A1 (en)	2017-05-24	2018-11-29	Formycon Ag	Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
WO2018215580A1 (en)	2017-05-24	2018-11-29	Formycon Ag	Method for sterilizing prefilled plastic syringes containing a vegf antagonist
US20200171244A1 (en)	2017-05-24	2020-06-04	Sio2 Medical Products, Inc.	Sterilizable pharmaceutical package for ophthalmic formulations
WO2019005640A2 (en) *	2017-06-25	2019-01-03	Systimmune, Inc.	MULTISPECIFIC ANTIBODIES AND METHODS OF MAKING AND USING SAME
WO2019020777A1 (en)	2017-07-26	2019-01-31	Formycon Ag	LIQUID FORMULATION OF A VEGF ANTAGONIST
FI3717636T3 (fi) *	2017-11-27	2023-06-01	4D Molecular Therapeutics Inc	Adenoassosioidun viruksen kapsidivariantteja ja käyttö angiogeneesin estämisessä
WO2019129679A1 (en) *	2017-12-29	2019-07-04	F. Hoffmann-La Roche Ag	Method for improving vegf-receptor blocking selectivity of an anti-vegf antibody
US11078283B2 (en)	2018-01-17	2021-08-03	Apexigen, Inc.	Anti-PD-L1 antibodies and methods of use
WO2019169341A1 (en)	2018-03-02	2019-09-06	Kodiak Sciences Inc.	Il-6 antibodies and fusion constructs and conjugates thereof
US20210017266A1 (en)	2018-03-16	2021-01-21	Novartis Ag	Methods for treating ocular diseases
EP3773914A1 (en) *	2018-04-06	2021-02-17	Eli Lilly and Company	Ramucirumab for the treatment of cancers in pediatric patients
CA3109361A1 (en)	2018-08-30	2020-03-05	HCW Biologics, Inc.	Single-chain and multi-chain chimeric polypeptides and uses thereof
CN113365663A (zh)	2018-08-30	2021-09-07	Hcw生物科技公司	单链嵌合多肽和其用途
US11518792B2 (en)	2018-08-30	2022-12-06	HCW Biologics, Inc.	Multi-chain chimeric polypeptides and uses thereof
WO2020056077A1 (en) *	2018-09-13	2020-03-19	The Board Of Regents Of The University Of Texas System	Novel lilrb4 antibodies and uses thereof
EP3856245A4 (en)	2018-09-24	2022-10-26	EyePoint Pharmaceuticals, Inc.	MULTISPECIFIC ANTIBODIES TARGETING HPTP-ß (VE-PTP) AND VEGF
WO2020128792A1 (en)	2018-12-18	2020-06-25	Novartis Ag	Protein solution formulation containing high concentration of an anti-vegf antibody
USD907456S1 (en)	2019-05-21	2021-01-12	Nomis Llc	Right angle drill attachment
USD907455S1 (en)	2019-05-21	2021-01-12	Nomis Llc	Right angle drive attachment
WO2020257639A1 (en)	2019-06-21	2020-12-24	HCW Biologics, Inc.	Multi-chain chimeric polypeptides and uses thereof
EP4028128A1 (en)	2019-09-13	2022-07-20	Novartis AG	Methods for treating ocular diseases
CN114786731A (zh)	2019-10-10	2022-07-22	科达制药股份有限公司	治疗眼部病症的方法
JP2023519107A (ja)	2020-02-11	2023-05-10	エイチシーダブリューバイオロジックスインコーポレイテッド	制御性ｔ細胞を活性化する方法
AU2021220870A1 (en)	2020-02-11	2022-08-04	Immunitybio, Inc.	Methods of treating age-related and inflammatory diseases
IL295084A (en)	2020-02-11	2022-09-01	Hcw Biologics Inc	Chromatography resin and its uses
WO2021174127A1 (en) *	2020-02-28	2021-09-02	Apexigen, Inc.	Anti-sirpa antibodies and methods of use
AU2021236302A1 (en) *	2020-03-12	2022-10-20	Immune-Onc Therapeutics, Inc.	Novel anti-LILRB4 antibodies and derivative products
JP2023517345A (ja)	2020-03-13	2023-04-25	ジェネンテック，インコーポレイテッド	抗インターロイキン－３３抗体及びその使用
CN115836087A (zh)	2020-04-29	2023-03-21	Hcw生物科技公司	抗cd26蛋白及其用途
WO2021247003A1 (en)	2020-06-01	2021-12-09	HCW Biologics, Inc.	Methods of treating aging-related disorders
IL298608A (en)	2020-06-01	2023-01-01	Hcw Biologics Inc	Methods for treating disorders related to aging
US12024545B2 (en)	2020-06-01	2024-07-02	HCW Biologics, Inc.	Methods of treating aging-related disorders
PE20231093A1 (es)	2020-07-16	2023-07-18	Novartis Ag	Anticuerpos anti-betacelulina, fragmentos de los mismos, y moleculas de union multiespecificas
JP2023546112A (ja)	2020-10-15	2023-11-01	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	長時間作用型眼送達用非共有結合タンパク質－ヒアルロナンコンジュゲート
TW202237181A (zh)	2020-11-25	2022-10-01	瑞士商諾華公司	治療眼部疾病之方法
WO2022201084A1 (en)	2021-03-26	2022-09-29	Novartis Ag	Methods for treating ocular diseases
EP4145456A1 (en)	2021-09-06	2023-03-08	Bayer AG	Prediction of a change related to a macular fluid
KR20230094450A (ko)	2021-12-21	2023-06-28	한림대학교 산학협력단	항-cldn18.2를 포함하는 키메릭 항원 수용체를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 및 이의 제조 방법
KR20240156626A (ko)	2022-03-02	2024-10-30	이뮤니티바이오, 인크.	췌장암의 치료 방법
TW202337496A (zh)	2022-03-17	2023-10-01	瑞士商諾華公司	治療新生血管性年齡相關性黃斑點退化之方法
CN117820474A (zh) *	2023-04-25	2024-04-05	南京贝思奥生物科技有限公司	改善眼部血管新生相关疾病的药物及其应用

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4275149A (en)	1978-11-24	1981-06-23	Syva Company	Macromolecular environment control in specific receptor assays
US4376110A (en)	1980-08-04	1983-03-08	Hybritech, Incorporated	Immunometric assays using monoclonal antibodies
US4737456A (en)	1985-05-09	1988-04-12	Syntex (U.S.A.) Inc.	Reducing interference in ligand-receptor binding assays
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en)	1986-03-27	2003-04-15	Btg International Limited	Altered antibodies
US5260203A (en)	1986-09-02	1993-11-09	Enzon, Inc.	Single polypeptide chain binding molecules
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US4881175A (en)	1986-09-02	1989-11-14	Genex Corporation	Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5013653A (en)	1987-03-20	1991-05-07	Creative Biomolecules, Inc.	Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5091513A (en)	1987-05-21	1992-02-25	Creative Biomolecules, Inc.	Biosynthetic antibody binding sites
JPH02500329A (ja)	1987-05-21	1990-02-08	クリエイテイブ・バイオマリキユールズ・インコーポレーテツド	ターゲット化多機能蛋白質
US5132405A (en)	1987-05-21	1992-07-21	Creative Biomolecules, Inc.	Biosynthetic antibody binding sites
US5258498A (en)	1987-05-21	1993-11-02	Creative Biomolecules, Inc.	Polypeptide linkers for production of biosynthetic proteins
WO1989006692A1 (en)	1988-01-12	1989-07-27	Genentech, Inc.	Method of treating tumor cells by inhibiting growth factor receptor function
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5147638A (en)	1988-12-30	1992-09-15	Oklahoma Medical Research Foundation	Inhibition of tumor growth by blockade of the protein C system
US5859205A (en)	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
OA10149A (en)	1991-03-29	1996-12-18	Genentech Inc	Vascular endothelial cell growth factor antagonists
US6582959B2 (en)	1991-03-29	2003-06-24	Genentech, Inc.	Antibodies to vascular endothelial cell growth factor
JP4124480B2 (ja)	1991-06-14	2008-07-23	ジェネンテック・インコーポレーテッド	免疫グロブリン変異体
DK1975181T3 (da)	1992-10-28	2011-06-06	Genentech Inc	Anvendelse af vaskulære endothelcelle-vækstfaktor-antagonister
IL117645A (en)	1995-03-30	2005-08-31	Genentech Inc	Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5730977A (en)	1995-08-21	1998-03-24	Mitsui Toatsu Chemicals, Inc.	Anti-VEGF human monoclonal antibody
CZ292465B6 (cs)	1996-02-09	2003-09-17	Abbott Laboratories (Bermuda) Ltd.	Lidské protilátky k lidskému TNFalfa
WO1998002462A1 (en) *	1996-07-16	1998-01-22	Morphosys Gesellschaft Für Proteinoptimierung Mbh	Immunoglobulin superfamily domains and fragments with increased solubility
WO2000053760A2 (en)	1999-03-12	2000-09-14	Genentech, Inc.	Method of preventing the death of retinal neurons and treating ocular diseases
US6986890B1 (en)	1996-11-21	2006-01-17	Kyowa Hakko Kogyo Co., Ltd.	Anti-human VEGF receptor Flt-1 monoclonal antibody
US20020032315A1 (en)	1997-08-06	2002-03-14	Manuel Baca	Anti-vegf antibodies
AU743758B2 (en) *	1997-04-07	2002-02-07	Genentech Inc.	Anti-VEGF antibodies
PT2301580E (pt) *	1997-04-07	2012-05-02	Genentech Inc	Recipiente contendo anticorpos anti-vegf
US20070059302A1 (en)	1997-04-07	2007-03-15	Genentech, Inc.	Anti-vegf antibodies
WO2000034337A1 (en)	1998-12-10	2000-06-15	Tsukuba Research Laboratory, Toagosei Co., Ltd.	Humanized monoclonal antibodies against vascular endothelial cell growth factor
US6703020B1 (en)	1999-04-28	2004-03-09	Board Of Regents, The University Of Texas System	Antibody conjugate methods for selectively inhibiting VEGF
US6887468B1 (en)	1999-04-28	2005-05-03	Board Of Regents, The University Of Texas System	Antibody kits for selectively inhibiting VEGF
WO2001030393A2 (en)	1999-10-22	2001-05-03	Ludwig Institute For Cancer Research	Methods for reducing the effects of cancers that express a33 antigen using a33 antigen specific immunoglobulin products
DE60012980T2 (de)	1999-12-28	2005-08-18	Esbatech Ag	Intrakörper mit definierter struktur ("framework"), die in einer reduzierenden umgebung stabil ist, und ihre verwendungen
GB0013810D0 (en)	2000-06-06	2000-07-26	Celltech Chiroscience Ltd	Biological products
US7667004B2 (en)	2001-04-17	2010-02-23	Abmaxis, Inc.	Humanized antibodies against vascular endothelial growth factor
DE10201450B4 (de)	2002-01-16	2004-09-02	Infineon Technologies Ag	Carry-Skip-Addierer für verschlüsselte Daten
US6576941B1 (en)	2002-02-20	2003-06-10	Samsung Electronics Co., Ltd.	Ferroelectric capacitors on protruding portions of conductive plugs having a smaller cross-sectional size than base portions thereof
CN1187373C (zh) *	2002-03-20	2005-02-02	上海中信国健药业有限公司	人源化抗血管内皮生长因子单克隆抗体及其制法和药物组合物
US8420353B2 (en)	2002-03-22	2013-04-16	Aprogen, Inc.	Humanized antibody and process for preparing same
CN103739706B (zh)	2002-05-22	2015-11-18	艾斯巴技术-诺华有限责任公司	在胞内环境中表现出增强的稳定性的免疫球蛋白构架及其鉴定方法
JP2005535341A (ja) *	2002-08-15	2005-11-24	エピトミスクインコーポレーティッド	ヒト化ウサギ抗体
EP2251355A1 (en)	2003-05-30	2010-11-17	Genentech, Inc.	Treatment with anti-VEGF antibodies
US20050048578A1 (en) *	2003-06-26	2005-03-03	Epitomics, Inc.	Methods of screening for monoclonal antibodies with desirable activity
US7758859B2 (en)	2003-08-01	2010-07-20	Genentech, Inc.	Anti-VEGF antibodies
US20050106667A1 (en) *	2003-08-01	2005-05-19	Genentech, Inc	Binding polypeptides with restricted diversity sequences
WO2005044853A2 (en) *	2003-11-01	2005-05-19	Genentech, Inc.	Anti-vegf antibodies
EP1651659A4 (en) *	2003-08-07	2008-09-17	Epitomics Inc	METHOD FOR HUMANIZATION OF MONOCLONAL RABBIT ANTIBODIES
ES2456943T3 (es)	2004-08-02	2014-04-24	Zenyth Operations Pty. Ltd.	Método de tratamiento de cáncer que comprende un antagonista de VEGF-B
PL1802334T3 (pl)	2004-10-21	2013-01-31	Genentech Inc	Sposób leczenia wewnątrzgałkowych chorób neowaskularnych
US7462697B2 (en) *	2004-11-08	2008-12-09	Epitomics, Inc.	Methods for antibody engineering
US7431927B2 (en) *	2005-03-24	2008-10-07	Epitomics, Inc.	TNFα-neutralizing antibodies
JP2009504685A (ja) *	2005-08-15	2009-02-05	アラーナ・テラピューティクス・リミテッド	新世界霊長類フレームワーク領域を用いる設計された抗体
AR059066A1 (es)	2006-01-27	2008-03-12	Amgen Inc	Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
WO2007140534A1 (en) *	2006-06-08	2007-12-13	Csl Limited	Vegf-a cross-reactive anti- vegf-b antibodies as antagonists of vegf-a and vegf-b signalling
EP2046382B1 (en)	2006-07-10	2016-08-17	ESBATech, an Alcon Biomedical Research Unit LLC	scFv ANTIBODIES WHICH PASS EPITHELIAL AND/OR ENDOTHELIAL LAYERS
US20100111963A1 (en)	2006-11-10	2010-05-06	Genentech, Inc.	Method for treating age-related macular degeneration
US7553486B2 (en)	2006-11-13	2009-06-30	Paul Theodore Finger	Anti-VEGF treatment for radiation-induced vasculopathy
SG10201503407WA (en)	2006-12-19	2015-06-29	Genentech Inc	Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
WO2008110348A1 (en)	2007-03-12	2008-09-18	Esbatech Ag	Sequence based engineering and optimization of single chain antibodies
CA2683791A1 (en)	2007-06-06	2008-12-11	Domantis Limited	Polypeptides, antibody variable domains & antagonists
KR20100040840A (ko)	2007-06-06	2010-04-21	도만티스 리미티드	폴리펩티드，항체 가변 도메인 및 길항제
CN106366192B (zh)	2007-06-25	2020-03-27	艾斯巴技术-诺华有限责任公司	修饰抗体的方法和具有改善的功能性质的修饰抗体
JP5506670B2 (ja)	2007-06-25	2014-05-28	エスバテック − アノバルティスカンパニーエルエルシー	単鎖抗体の配列に基づくエンジニアリング及び最適化
EP2259795B1 (en) *	2008-03-26	2016-04-06	Epitomics, Inc.	Anti-vegf antibody
EP2752428B8 (en) *	2008-06-25	2020-02-26	Novartis Ag	Humanization of rabbit antibodies using a universal antibody framework
ES2629345T3 (es)	2008-06-25	2017-08-08	Esbatech, An Alcon Biomedical Research Unit Llc	Optimización de la solubilidad de agentes de unión inmunológica
KR101737466B1 (ko) *	2008-06-25	2017-05-18	에스바테크 - 어 노바티스 컴파니 엘엘씨	Ｖｅｇｆ를 억제하는 안정하고 가용성인 항체
WO2010003268A2 (en) *	2008-07-10	2010-01-14	Esbatech, An Alcon Biomedical Research Unit Llc	Methods and compositions for enhanced delivery of macromolecules
KR20170084357A (ko) *	2009-12-23	2017-07-19	에스바테크 - 어 노바티스 컴파니 엘엘씨	면역원성의 감소 방법

2009
- 2009-06-25 KR KR1020167030125A patent/KR101737466B1/ko active IP Right Grant
- 2009-06-25 RU RU2014132888A patent/RU2588467C3/ru active Protection Beyond IP Right Term
- 2009-06-25 CA CA3020290A patent/CA3020290A1/en active Pending
- 2009-06-25 JP JP2011515049A patent/JP5956752B2/ja active Active
- 2009-06-25 KR KR1020117001961A patent/KR102013220B1/ko active Protection Beyond IP Right Term
- 2009-06-25 HU HUE09768693A patent/HUE032894T2/hu unknown
- 2009-06-25 SI SI200931647A patent/SI2307454T1/sl unknown
- 2009-06-25 MX MX2011000011A patent/MX2011000011A/es active IP Right Grant
- 2009-06-25 KR KR1020197022648A patent/KR102157097B1/ko active Application Filing
- 2009-06-25 CN CN201910338494.7A patent/CN110372792A/zh active Pending
- 2009-06-25 PL PL17151756T patent/PL3216803T3/pl unknown
- 2009-06-25 KR KR1020207026266A patent/KR102296443B1/ko active IP Right Grant
- 2009-06-25 DK DK09768693.5T patent/DK2307454T3/en active
- 2009-06-25 ES ES09768693.5T patent/ES2622470T3/es active Active
- 2009-06-25 KR KR1020177012884A patent/KR101817284B1/ko active IP Right Grant
- 2009-06-25 BR BRPI0914251-7A patent/BRPI0914251B1/pt active IP Right Grant
- 2009-06-25 EP EP17151756.8A patent/EP3216803B1/en active Active
- 2009-06-25 CA CA2727839A patent/CA2727839C/en active Active
- 2009-06-25 PT PT97686935T patent/PT2307454T/pt unknown
- 2009-06-25 CN CN201510205513.0A patent/CN104961828B/zh active Active
- 2009-06-25 EP EP09768693.5A patent/EP2307454B1/en active Active
- 2009-06-25 KR KR1020187000324A patent/KR20180005753A/ko active IP Right Grant
- 2009-06-25 ES ES17151756T patent/ES2793008T3/es active Active
- 2009-06-25 SI SI200932061T patent/SI3216803T1/sl unknown
- 2009-06-25 LT LTEP17151756.8T patent/LT3216803T/lt unknown
- 2009-06-25 DK DK17151756.8T patent/DK3216803T3/da active
- 2009-06-25 EP EP20158159.2A patent/EP3722310B1/en active Active
- 2009-06-25 AU AU2009264565A patent/AU2009264565C1/en active Active
- 2009-06-25 WO PCT/CH2009/000220 patent/WO2009155724A2/en active Application Filing
- 2009-06-25 US US13/000,423 patent/US8349322B2/en active Active
- 2009-06-25 KR KR1020187024733A patent/KR102095257B1/ko active Protection Beyond IP Right Term
- 2009-06-25 MX MX2013004871A patent/MX347972B/es unknown
- 2009-06-25 HU HUE17151756A patent/HUE050230T2/hu unknown
- 2009-06-25 PT PT171517568T patent/PT3216803T/pt unknown
- 2009-06-25 CN CN200980124313.5A patent/CN102143976B/zh active Active
- 2009-06-25 KR KR1020157032314A patent/KR101671886B1/ko active Protection Beyond IP Right Term
- 2009-06-25 RU RU2011102583A patent/RU2531523C3/ru active
- 2009-06-25 PL PL09768693T patent/PL2307454T3/pl unknown
- 2009-06-25 LT LTEP09768693.5T patent/LT2307454T/lt unknown
2010
- 2010-11-30 ZA ZA2010/08594A patent/ZA201008594B/en unknown
- 2010-12-23 CL CL2010001544A patent/CL2010001544A1/es unknown
2011
- 2011-05-19 HK HK11104959.8A patent/HK1150844A1/zh unknown
2012
- 2012-12-07 US US13/708,575 patent/US9090684B2/en active Active
2013
- 2013-07-19 RU RU2013133802/10A patent/RU2013133802A/ru not_active Application Discontinuation
2014
- 2014-04-21 JP JP2014087194A patent/JP6100199B2/ja active Active
2015
- 2015-02-27 JP JP2015037794A patent/JP2015134792A/ja active Pending
- 2015-06-16 US US14/741,430 patent/US9873737B2/en active Active
- 2015-07-20 PH PH12015501593A patent/PH12015501593A1/en unknown
2016
- 2016-05-18 RU RU2016119152A patent/RU2648152C2/ru active
- 2016-12-28 JP JP2016255720A patent/JP6527128B2/ja active Active
2017
- 2017-04-12 CY CY20171100436T patent/CY1118829T1/el unknown
- 2017-04-18 HR HRP20170615TT patent/HRP20170615T1/hr unknown
- 2017-11-16 US US15/814,784 patent/US10590193B2/en active Active
2018
- 2018-02-05 JP JP2018018375A patent/JP6821612B2/ja active Active
- 2018-02-16 RU RU2018105866A patent/RU2696972C1/ru active
2019
- 2019-05-13 JP JP2019090735A patent/JP6978468B2/ja active Active
- 2019-06-27 RU RU2019120079A patent/RU2747735C3/ru active
2020
- 2020-01-31 US US16/779,028 patent/US20200172608A1/en not_active Abandoned
- 2020-05-19 HR HRP20200814TT patent/HRP20200814T1/hr unknown
- 2020-06-05 CY CY20201100507T patent/CY1123028T1/el unknown
- 2020-07-23 LT LTPA2020004C patent/LTC2307454I2/lt unknown
- 2020-07-27 HU HUS2000028C patent/HUS2000028I1/hu unknown
- 2020-07-28 NL NL301058C patent/NL301058I2/nl unknown
- 2020-07-30 CY CY2020026C patent/CY2020026I2/el unknown
- 2020-08-04 NO NO2020021C patent/NO2020021I1/no unknown
2021
- 2021-11-11 JP JP2021184262A patent/JP7171877B6/ja active Active

Also Published As

Publication number	Publication date
JP2022020782A (ja)	2022-02-01
LT3216803T (lt)	2020-06-10
KR20160128458A (ko)	2016-11-07
HUS2000028I1 (hu)	2020-08-28
EP3722310B1 (en)	2024-08-28
MX347972B (es)	2017-05-22
KR20180098705A (ko)	2018-09-04
RU2588467C3 (ru)	2021-10-20
RU2016119152A (ru)	2017-11-21
RU2531523C2 (ru)	2014-10-20
KR101737466B1 (ko)	2017-05-18
JP2011525359A (ja)	2011-09-22
JP5956752B2 (ja)	2016-07-27
US9873737B2 (en)	2018-01-23
US20150274820A1 (en)	2015-10-01
US20180072802A1 (en)	2018-03-15
NO2020021I1 (no)	2020-08-04
WO2009155724A2 (en)	2009-12-30
ZA201008594B (en)	2012-02-29
CL2010001544A1 (es)	2012-02-03
CN104961828B (zh)	2019-03-26
US20120014958A1 (en)	2012-01-19
WO2009155724A3 (en)	2010-04-01
RU2696972C1 (ru)	2019-08-07
DK2307454T3 (en)	2017-04-24
MX2011000011A (es)	2011-09-27
RU2019120079A (ru)	2020-12-28
CY2020026I1 (el)	2020-11-25
EP3216803A1 (en)	2017-09-13
CN104961828A (zh)	2015-10-07
US9090684B2 (en)	2015-07-28
RU2747735C3 (ru)	2022-05-04
JP6100199B2 (ja)	2017-03-22
NL301058I1 (hu)	2020-07-31
JP2017055774A (ja)	2017-03-23
HUE032894T2 (hu)	2017-11-28
SI2307454T1 (sl)	2017-05-31
KR20200108922A (ko)	2020-09-21
PL3216803T3 (pl)	2020-10-19
RU2014132888A (ru)	2015-12-10
RU2747735C2 (ru)	2021-05-13
LTPA2020004I1 (lt)	2020-08-10
US8349322B2 (en)	2013-01-08
SI3216803T1 (sl)	2020-07-31
KR101817284B1 (ko)	2018-01-11
RU2019120079A3 (hu)	2020-12-28
JP2015134792A (ja)	2015-07-27
BRPI0914251B1 (pt)	2022-07-19
EP2307454B1 (en)	2017-01-18
JP7171877B6 (ja)	2024-02-06
KR20170057462A (ko)	2017-05-24
DK3216803T3 (da)	2020-06-02
CY1118829T1 (el)	2018-01-10
LT2307454T (lt)	2017-05-25
RU2011102583A (ru)	2012-07-27
JP7171877B2 (ja)	2022-11-15
LTC2307454I2 (lt)	2021-05-25
PL2307454T3 (pl)	2017-07-31
RU2013133802A (ru)	2015-01-27
BRPI0914251A2 (pt)	2021-01-05
HK1150844A1 (zh)	2012-01-13
KR102296443B1 (ko)	2021-09-01
RU2531523C3 (ru)	2022-05-04
US20140004114A1 (en)	2014-01-02
JP6821612B2 (ja)	2021-01-27
CN102143976B (zh)	2015-11-25
PT3216803T (pt)	2020-06-16
EP2307454A2 (en)	2011-04-13
RU2531523C9 (ru)	2015-04-10
EP3216803B1 (en)	2020-03-11
CN102143976A (zh)	2011-08-03
ES2793008T3 (es)	2020-11-12
CA3020290A1 (en)	2009-12-30
KR20110028518A (ko)	2011-03-18
US10590193B2 (en)	2020-03-17
KR20150132602A (ko)	2015-11-25
JP6527128B2 (ja)	2019-06-05
HRP20200814T1 (hr)	2020-08-07
JP2018108081A (ja)	2018-07-12
CN110372792A (zh)	2019-10-25
KR101671886B1 (ko)	2016-11-04
KR102013220B1 (ko)	2019-08-23
KR102095257B1 (ko)	2020-04-01
PT2307454T (pt)	2017-04-26
AU2009264565A1 (en)	2009-12-30
KR20180005753A (ko)	2018-01-16
HRP20170615T1 (hr)	2017-07-28
JP2014158491A (ja)	2014-09-04
EP3722310A1 (en)	2020-10-14
ES2622470T3 (es)	2017-07-06
CY2020026I2 (el)	2020-11-25
NL301058I2 (nl)	2020-10-27
JP6978468B2 (ja)	2021-12-08
CY1123028T1 (el)	2021-10-29
AU2009264565C1 (en)	2022-01-27
JP2019162127A (ja)	2019-09-26
RU2648152C2 (ru)	2018-03-22
AU2009264565B2 (en)	2014-05-08
PH12015501593A1 (en)	2015-12-14
KR102157097B1 (ko)	2020-09-18
KR20190092630A (ko)	2019-08-07
CA2727839A1 (en)	2009-12-30
US20200172608A1 (en)	2020-06-04
CA2727839C (en)	2018-11-20

Publication	Publication Date	Title
HUS2000028I1 (hu)	2020-08-28	VEGF-gátló, stabilis és oldható antitestek
ZA201308787B (en)	2016-08-31	Stable and soluble antibodies inhibiting tnfa
IL209309A0 (en)	2011-01-31	Anti-fn14 antibodies and uses thereof
IL216731A (en)	2015-04-30	And antibodies against p95 – her2 and their uses
EP2241578A4 (en)	2012-09-12	ANTI-CLDN6 ANTIBODIES
ZA201102119B (en)	2011-12-28	Improved antibody libraies
HK1195776A1 (zh)	2014-11-21	-α 抗-α 抗體及其應用
PL2630159T3 (pl)	2018-04-30	Stabilne i rozpuszczalne przeciwciała
IL220536A0 (en)	2012-08-30	Anti - bv8 antibodies and uses thereof
EP2388320A4 (en)	2012-11-07	ANTI-HS6ST2 ANTIBODIES AND USE THEREOF
IL214527A0 (en)	2011-09-27	Anti-mst1r antibodies and uses thereof
GB0812277D0 (en)	2008-08-13	Antibody and uses thereof
GB0911770D0 (en)	2009-08-19	Antibody
GB0906115D0 (en)	2009-05-20	Antibody and uses thereof
GB0817622D0 (en)	2008-11-05	Antibody
GB0817621D0 (en)	2008-11-05	Antibody
LT2630159T (lt)	2018-03-12	Stabilūs ir tirpūs antikūnai